Pro Medicus Limited [ASX: PME] announced a A$43 million, seven-year contract with Virtua Health, a leading academic health system in South Jersey, New Jersey. The deal represents a significant commercial milestone for the company’s cloud-based Visage 7 imaging platform and shows the accelerating adoption of unified enterprise imaging solutions in the North American healthcare market. The contract demonstrates Pro Medicus’ ability to secure large-scale deployments with established healthcare institutions and highlights the growing shift toward cloud-based solutions in the medical imaging sector.
Virtua operates five hospitals across South Jersey and serves 15,000 colleagues alongside 3,000 affiliated doctors and clinicians. The health system maintains academic partnerships with Rowan University, Penn Medicine, and the Children’s Hospital of Philadelphia. Under this contract, Pro Medicus will deploy its full Visage 7 suite across Virtua’s enterprise, encompassing the Viewer, Workflow, Open Archive, and Cardiology Imaging components. The platform will operate entirely in the cloud and includes the critical technical undertaking of migrating Virtua’s legacy PACS archives to Visage 7 Open Archive. Visage 7 will also provide integrated image distribution to Virtua’s electronic health record systems. Pro Medicus expects planning to commence immediately with go-live targeted for late Q2 or early Q3 2027.
The contract structure offers insights into Pro Medicus’ commercial evolution. The transaction-based licensing model, rather than traditional software licensing, allows the company to align revenue recognition with actual usage patterns and generates recurring income streams. This approach also creates potential for upside capture as the customer base grows within the Virtua system. The shift toward this model reflects the company’s CloudPACS strategy and positions Pro Medicus to benefit from increasing digitalization of healthcare workflows across North America.
The Virtua deal demonstrates multiple strategic strengths. The inclusion of Cardiology Imaging alongside core archive and workflow components shows another major customer adopting Pro Medicus’ full-stack offering. CEO Dr Sam Hupert highlighted this consolidation trend, noting that more healthcare enterprises are looking to replace disparate legacy imaging systems with unified solutions from a single vendor. Management indicated the company’s pipeline remains strong across all market segments and that interest continues to grow for comprehensive solutions incorporating viewer, workflow, archive, and specialty modules.
Investors should track progress toward the 2027 implementation timeline and monitor how many subsequent pipeline deals incorporate similar full-stack deployments. Success in this transition to cloud-based recurring revenue models could validate the CloudPACS strategy as the dominant architecture in North American healthcare IT, potentially widening Pro Medicus’ addressable market. This announcement has been declared price sensitive and flagged as material by the ASX.
Our exclusive top 5 stock picks
Five high conviction stocks that didn't make the public list. Backed by institutional research. Subscribe for free access.
Thanks for subscribing, please check your email to confirm your subscription to instantly access your report.
View the full ASX announcement (PDF)
About Pro Medicus Limited (ASX: PME)
Pro Medicus Limited is an Australian health imaging software company headquartered in Victoria that develops advanced diagnostic imaging solutions for the global healthcare market. The company’s main business segment centers on its Visage imaging platform, a viewer and analysis solution used by hospitals and medical institutions to manage and interpret medical images. Pro Medicus operates primarily through its U.S. subsidiary Visage Imaging, Inc., serving major healthcare systems across North America and internationally on a transaction-based licensing model.
If you would like to discuss this announcement, request a callback or call us on 1300 889 603.